等待開盤 03-26 09:30:00 美东时间
+0.700
+32.41%
VivoPower PLC (NASDAQ: VIVO) shares are trading sharply higher Wednesday afternoon as investors react to a pair of recent company moves aimed at reducing dilution and tightening the stock's publicly tradable float.
今天 01:37
BRIEF-Vivopower Commences Strategic Share Conversion Program March 20 (Reuters) - VivoPower PLC VIVO.O : VIVOPOWER COMMENCES STRATEGIC SHARE CONVERSION PROGRAM; INITIAL 2.96 MILLION LISTED CLASS A ORDINARY SHARES BECOMING UNLISTED RESTRICTED CLASS B SHARES, REDUCING PUBLIC FLOAT Source text: ID:nGNX
03-20 22:36
Follows recently announced share acquisitions totaling 2.65 million shares by board members, including Executive Chairman and CEO, Kevin Chin, who purchased the majority of shares Conversion program is aligned with
03-20 21:35
VivoPower's executive chairman Kevin Chin and other board members have voluntarily converted 2.96 million NASDAQ-listed Class A ordinary shares into unlisted Class B ordinary shares to reinforce their long-term commitment and governance alignment. This follows recent share acquisitions totaling 2.65 million shares led by Chin, aimed at minimizing dilution and enhancing shareholder interests. The dual-class structure aligns with the company's capi...
03-20 13:32
VivoPower PLC (Nasdaq: VIVO) ("VivoPower" or the "Company"), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that it has
03-18 21:03
BRIEF-Vivopower Terminates $180 Million F-3 Registration Statement March 18 (Reuters) - VivoPower PLC VIVO.O : VIVOPOWER TERMINATES $180 MILLION F-3 REGISTRATION STATEMENT VIVOPOWER PLC - NO FURTHER SALES OF ORDINARY SHARES UNDER F-3 REGISTRATION STATEMENT Source text: ID:nGNX8PDJF4 Further company
03-18 21:01
VivoPower PLC has terminated its Form F-3 registration statement, ceasing sales of ordinary shares under this filing. This decision reflects the Board's commitment to a non-dilutive capital strategy and confidence in the Company's current cash flows and alternative funding sources. Established in 2014 and listed on Nasdaq since 2016, VivoPower specializes in developing sustainable data center infrastructure for sovereign nations to support their ...
03-18 13:00
Vivos Therapeutics发布新数据显示,其FDA认证的DNA设备能有效缓解儿童ADHD和阻塞性睡眠呼吸暂停(OSA)症状。该设备是非手术、非药物治疗中重度OSA的创新方案,临床试验显示患儿症状改善显著。
2025-09-30 12:30
下一个超级赛道,或许就是固态电池。 9月18日,松下控股旗下的松下能源公司宣布,将致力于生产被视为新一代电池热门候选的“全固态电池”。此外,据测算这一技术能够使...
2025-09-19 09:29
Vivos Therapeutics' Vivos DNA appliance, part of the C.A.R.E. line, has been proven safe and effective in treating children with obstructive sleep apnea (OSA) in a multicenter clinical trial published in *The European Journal of Pediatrics*. The study showed that 77% of participants experienced at least a 50% reduction in OSA severity, and 93% of severe cases achieved this reduction. The appliance increases airway volume by 67.8% and reduces slee...
2025-09-17 12:30